SRF and fibrosis: For example, CCG-222740 is reported to be five times more potent than CCG-203971 in inhibiting MRTF/SRF target genes and effectively reduces scar tissue formation in fibrosis models while exhibiting lower cytotoxicity than earlier inhibitors do [185].